165 related articles for article (PubMed ID: 37578571)
1. In vitro characterisation of [
Hull A; Hsieh W; Tieu W; Bartholomeusz D; Li Y; Bezak E
EJNMMI Radiopharm Chem; 2023 Aug; 8(1):18. PubMed ID: 37578571
[TBL] [Abstract][Full Text] [Related]
2. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
[TBL] [Abstract][Full Text] [Related]
3. Development of [
Hull A; Hsieh W; Borysenko A; Tieu W; Bartholomeusz D; Bezak E
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):22. PubMed ID: 37679594
[TBL] [Abstract][Full Text] [Related]
4. The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy.
Hull A; Li Y; Bartholomeusz D; Hsieh W; Escarbe S; Ruszkiewicz A; Bezak E
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33379259
[TBL] [Abstract][Full Text] [Related]
5. Relative Biological Effectiveness (RBE) of [
Boyle AJ; Cai Z; O'Brien S; Crick J; Angers S; Reilly RM
Nucl Med Biol; 2023; 122-123():108367. PubMed ID: 37506639
[TBL] [Abstract][Full Text] [Related]
6. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.
Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ
Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
9. SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a
Sachindra S; Hellberg T; Exner S; Prasad S; Beindorff N; Rogalla S; Kimura R; Gambhir SS; Wiedenmann B; Grötzinger C
Front Oncol; 2021; 11():684713. PubMed ID: 34136410
[TBL] [Abstract][Full Text] [Related]
10. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.
Song EY; Qu CF; Rizvi SM; Raja C; Beretov J; Morgenstern A; Apostolidis C; Bruchertseifer F; Perkins A; Allen BJ
Cancer Biol Ther; 2008 Jan; 7(1):76-80. PubMed ID: 18347423
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to
Aghevlian S; Cai Z; Lu Y; Hedley DW; Winnik MA; Reilly RM
Mol Pharm; 2019 Feb; 16(2):768-778. PubMed ID: 30589553
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
13. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer.
Wang L; Chen H; Liu F; Madigan MC; Power CA; Hao J; Patterson KI; Pourgholami MH; O'Brien PM; Perkins AC; Li Y
Cancer Lett; 2011 Jan; 300(2):122-33. PubMed ID: 21075513
[TBL] [Abstract][Full Text] [Related]
15. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
17. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
18. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
19. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
20. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]